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Most B-cell lymphomas arise in the germinal center
(GC), where humoral immune responses evolve
from potentially oncogenic cycles of mutation, prolif-
eration, and clonal selection. Although lymphoma
gene expression diverges significantly from GC B
cells, underlying mechanisms that alter the activities
of corresponding regulatory elements (REs) remain
elusive. Here we define the complete pathogenic
circuitry of human follicular lymphoma (FL), which
activates or decommissions REs from normal GC
B cells and commandeers enhancers from other
lineages. Moreover, independent sets of transcrip-
tion factors, whose expression was deregulated
in FL, targeted commandeered versus decommis-
sioned REs. Our approach revealed two distinct
subtypes of low-grade FL, whose pathogenic cir-
cuitries resembled GC B or activated B cells. FL-
altered enhancers also were enriched for sequence
variants, including somatic mutations, which disrupt
transcription-factor binding and expression of cir-
cuit-linked genes. Thus, the pathogenic regulatory
circuitry of FL reveals distinct genetic and epigenetic
etiologies for GC B-cell transformation.
INTRODUCTION
B-cell lymphoma is one of the most common human cancers.
Its prevalence is a byproduct of the complex cellular and molec-
ular processes that tailor humoral immune responses to antigens
in the germinal center (GC). In secondary lymphoid organs, GC B
cells undergo clonal expansion while activation-induced cytidine
deaminase (AICDA) targets their genomes for DNA damage-
associated alterations. In the GC dark zone, proliferative centro-
blasts (CBs) perform somatic hypermutation (SHM) to fine-tune
the affinity of immunoglobulin (Ig) variable regions for their
cognate antigens. Some of the CBs then migrate to the light
zone, where they become non-cycling centrocytes (non-cycling186 Immunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc.CCs), are selected for antigen affinity, and undergo class-switch
recombination (Allen et al., 2007). Recent studies indicate that,
rather than representing two distinct stages of differentiation,
CCs and CBs are alternate activation states of GC B cells (Vic-
tora et al., 2012).
Although essential for optimization of humoral responses, the
GC reaction involves coincident genome damage and rapid
proliferation that increase the risk of the oncogenic lesions
that underlie most types of B-cell lymphoma (Rui et al.,
2011). For example, follicular lymphoma (FL), a common form
of non-Hodgkin lymphoma (NHL), is thought to arise from
CCs (Victora et al., 2012). The pathologic hallmark of FL is an
AICDA-mediated t(14;18) [IgH-BCL2] translocation and causes
overexpression of the anti-apoptotic BCL2 protein (Leich et al.,
2011). However, this primary genetic lesion is insufficient to
initiate FL. Indeed, BCL2 transgenic mice infrequently develop
FL, and t(14;18)-bearing B cells are found in healthy individuals
who do not develop lymphoma (Cheung et al., 2009; Do¨lken
et al., 1996). A fundamental focus of lymphoma biology remains
the identification of cooperative mechanisms that promote
oncogenesis.
One clear outcome of these cooperativemechanisms is a sub-
stantial revision of normal GC expression programs during trans-
formation of GC cells to NHL (Klein and Dalla-Favera, 2008),
which culminates from a combination of genetic and epigenetic
changes. First, compared with GC B cells, NHL samples have
altered expression of at least some transcription factors (TFs)
that are essential to the GC reaction (Alizadeh et al., 2000). Sec-
ond, NHL samples have mutations in histone modifiers, leading
to altered chromatin landscapes (Morin et al., 2011; Yap et al.,
2011). These epigenomic perturbations might coordinately
silence large cohorts of genes (e.g., tumor suppressors) while
activating genes involved in proliferation (Baylin and Jones,
2011). Third, many diseases are commonly linked to genetic or
epigenetic differences in non-coding sequences that encom-
pass transcriptional regulatory elements (REs) (Akhtar-Zaidi
et al., 2012; Maurano et al., 2012). This shared genetic–epige-
netic etiology may be especially relevant to NHL because of its
inherent genome instability and dysregulation of histone modi-
fiers, both of which could impact RE function.
To understand the oncogenic processes that sculpt NHL tran-
scriptomes, it is critical to identify altered distal REs (DREs) and
assign them to target genes, thereby defining pathogenic cir-
cuitry that drives cellular transformation. Analyses of chromatin
modification patterns have linked some DREs with their target
promoters in normal cells, revealing aspects of lineage-specific
regulatory circuits (Gerstein et al., 2012; Maurano et al., 2012).
To decipher oncogenic changes to regulatory circuits, one
should compare purified malignant cells from primary tumors
with normal counterparts rather than using unsorted biopsy
samples containing amixture of cell types, or cancer lines, which
accumulatewidespread revisions to the genome and epigenome
during long-term culture (Masters, 2000; Victora et al., 2012).
To circumvent these obstacles, we focused on FL, an indolent
B-cell malignancy that is incurable and often transforms to a
more aggressive lymphoma (Lenz and Staudt, 2010).
We report an integrative analysis of -omics data from purified
human FL B cells and their normal GC B counterparts, exposing
the oncogenic regulatory circuitry of this cancer. The FL cir-
cuitry is a composite of enhancers that are engaged normally
in CC or CB subsets but are chronically activated or attenuated
in FL, as well as DREs usurped from a wide range of other, non-
B lineages. Importantly, augmented or attenuated DREs are
each targeted by a distinct set of TFs that exhibit altered
expression in FL. Our approach also revealed two previously
unappreciated subtypes of low-grade FL; these subtypes
have distinct expression profiles and corresponding sets of
aberrant DREs. The FL-altered DREs are also enriched for dis-
ease-associated single-nucleotide polymorphisms (SNPs) and,
remarkably, for somatic mutations. Indeed, several of the vari-
ants, located in attenuated DREs, impair binding of TFs that
play key roles in GC reactions and correspond to reductions
in target gene expression. These discoveries establish the
epigenetic and genetic etiologies that mediate transformation
of normal GC B cells into a common cancer, and they pave
the way for personalized epigenetic therapies that target sub-
type-specific control elements.
RESULTS
The FL Regulome Reflects Its Centrocyte Origins
Rewiring of gene expression in cancer evolves from a series of
genetic and epigenetic changes that impinge on the activities
of transcriptional promoters and their DREs. Deciphering how
these processes drive cancer requires characterization of regu-
lomes in purified malignant cells and comparison of these cells
with their normal counterparts. Thus, we purified malignant B
cells from lymph-node biopsies of 18 FL patients (Table S1).
Control B cells were purified from the peripheral blood of healthy
individuals (these cells are referred to as PBBs), FL patients, and
excised tonsils (the latter are referred to as TsBs). Chromatin,
RNA, and genomic DNA harvested from these samples were
analyzed by ChIP-seq, SNP arrays, and either RNA-seq or
expression arrays, respectively. We used FAIRE-seq to identify
putative cis elements in each sample (Giresi and Lieb, 2009)
and analyzed hallmark chromatin features (Bernstein et al.,
2012), including H3K27ac and H3ac, to assess relative RE activ-
ities among B-cell populations. To standardize comparisons be-
tween samples, we normalized the data for differences in read
depth andmerged overlapping peaks to generate a consolidated
list of putative REs.On the basis of gene expression profiles, cells of FL and
diffuse large B-cell lymphoma (DLBCL) most closely resemble
GC B cells (Victora et al., 2012). We purified CCs and
CBs from human tonsils by using flow cytometry and the
following surface markers: CD19+CD10+CD44loCXCR4+ (CBs)
and CD19+CD10+CD44loCXCR4- (CCs). Successful separation
was confirmed by comparison of the expression of genes known
to discriminate CCs from CBs (Figure S1A). Importantly, the
close relationship between CCs and CBs, compared with other
hematopoietic lineages, is evident from clustering analyses of
open chromatin regions (Figure S1B), underscoring the strong
functional links between regulomes and transcriptomes.
To determine the most appropriate control cell type for
defining pathogenic FL circuitry, we first compared expression
of genes that distinguish CCs from CBs (Victora et al., 2012).
Consistent with a previous study, expression of these genes in
FL is similar to CC expression and diverges almost completely
from CB expression (Figure 1A). In contrast, cultured NHL cell
lines resemble the highly proliferative CB subset. Epigenomic
analyses complement these transcriptome comparisons; the
majority of REs in FL are sharedwith GCB cells, though a greater
proportion overlapwith CCs thanwith CBs (Figure 1B). Together,
these data support the notion that FL arises from CCs (Victora
et al., 2012) and that comparison to CCs should be used for iden-
tification of REs with altered function in FL.
Defining the FL-Altered Regulome
Pathogenic gene expression in many diseases, including cancer,
is caused by changes in DRE activity. These changes in turn
alter promoter function (Akhtar-Zaidi et al., 2012). Accordingly,
we set out to identify DREs whose activities in FL samples were
augmented or attenuated in comparison to those of normal CCs.
Although FAIRE-seq data mark DRE locations in the genome,
bothpoisedandactiveciselementsemergeaspeaks.Tomeasure
the relative activity of DREs, we incorporated ChIP-seq data for
H3K27ac andH3ac,whichmark activeDREs. For example, nearly
identical FAIRE peaks are detected in bothCCand FL samples for
a cis element located near CXCR4 (Figure 1C), which encodes a
chemokine receptor required for light- (CC)anddark (CB)-zoneor-
ganization (Allen et al., 2007). This region is substantially enriched
forH3K27ac inFLsamples, indicatingaugmentedactivity. Indeed,
FL samples also exhibited higher CXCR4 expression than did CC
controls. A global view of H3K27ac levels at DREs in FL and GCB
cells segregates these regions into multiple categories on the
basis of relative activity, including FL hyper-activation or attenua-
tion ofDREs characteristic ofCCs, CBs, or neither of these closely
related subsets (Figure 1D).
To define the FL dysregulome, we assigned variable DREs as
regions for which FAIRE, H3K27ac, or H3ac intensity for an indi-
vidual lymphoma differ more than two-fold from averaged values
for the same regions in CC samples. As expected from similar-
ities between FL cells and CCs, the majority of REs remain un-
changed in lymphoma B cells, and the remainder exhibit altered
signal intensity (15K–30K per FL sample). In nearly all FL sma-
ples, more DREs are attenuated, though a substantial proportion
exhibit enhanced activity (25%–55%) (Figure 1E). Epigenetic
alteration of DREs cannot be attributed exclusively to mutations
in chromatin modifiers because these occurred in only a subset
of samples (Table S2). As shown in Figure S1C, H3K27ac peakImmunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc. 187
Figure 1. The Centrocyte Origins and Alterations to the FL Regulome
(A) Expression profiles of FL and NHL cell lines for a panel of genes differentially expressed in CBs versus CCs.
(B) Bar graph showing unique and shared FAIRE peaks in FL and GC B-cell populations.
(C) UCSC Genome Browser views of FAIRE-seq, H3K27ac ChIP-seq and RNA-seq data from FL and CC samples, illustrating a collection of DREs located near
CXCR4. FAIRE and ChIP data are presented as the number of reads per million mapped reads and are plotted on an axis of 1–25 (FAIRE) and 1–90 (H3K27ac).
RNA data are presented as the number of aligned, in silico extended reads per 10 bp on a scale of 1–400 reads.
(D) H3K27acChIP-seq intensities for DREs in representative CB, CC, and FL samples. Data are presented as k-means clustering of tag densities per 200 bpwithin
a window of 10 kb around the DREs.
(E) Percent of variable DREswith a 2-fold or greater increase (augmented) or decrease (attenuated) in FAIRE-seq, H3acChIP-seq, or H3K27acChIP-seq signal for
FL samples relative to CC samples.
(F) Recurrence rates of variable DREs are depicted by the proportion detected in a certain number of FL samples.intensity in CC control samples is highly reproducible; less
than 5% of DREs are variable in CC samples, whereas 45%–
50% of these elements are variable in FL samples (Figure S1D).
Augmented or attenuated DRE intensities were also similar
between FL and patient-matched PBBs or any of theCC controls
(Figure S1E). Underscoring their relevance to common pathways
of lymphomagenesis, the majority of variable DREs are recur-
rent, and more than 80% were identified in at least two FL sam-
ples (Figure 1F).
The genomic location of variable DREs—in distal, non-pro-
moter regions—along with their epigenetic profiles (FAIRE+
H3K27ac+) indicates enhancer function. Indeed, luciferase188 Immunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc.reporter assays revealed enhancer activity for 7/10 DREs in
cultured lymphoma cells (Figure S1F). A subtype of DRE, termed
super-enhancers (SEs), are composed of large RE clusters and
drive the expression of lineage-specifying genes (Hnisz et al.,
2013; Whyte et al., 2013). In addition, SEs might contribute to
pathologic gene expression in DLBCL (Chapuy et al., 2013). To
evaluate the variability of SEs in FL samples versus CCs, we
identified these elements by their unusually high H3K27ac den-
sity (Figure S1G and Table S3) (Whyte et al., 2013). Consistent
with previous reports, genes within 500 kb of SEs were ex-
pressed more robustly than those near conventional enhancers
(Figure S1H). Using our criteria, one can categorize a subset
Figure 2. Pathogenic Circuitry of FL
(A) Number of TSSs for which chromatin alterations are concordant with nearby variable DREs (within 500 kb).
(B) Mean transcript abundance as determined by RNA-Seq for genes linked to augmented, unchanged, or attenuated DREs and located within the distances
shown from the DREs. Statistical significance (Mann-Whitney test): *p % 0.05, **p % 0.01, and ****p % 0.0001. Results represent the mean ± SEM of ten FL
samples.
(C) UCSC Genome Browser views of H3K27ac ChIP-seq data, showing augmented DREs (highlighted in blue). RNA-seq data depict the corresponding upre-
gulation of mRNA from DRE target genes. The bottom track shows significant spatial interactions in GM12878 B cells (ENCODE, 5C data) between restriction
fragments encompassing the DREs and restriction fragments near the target-gene TSSs (Sanyal et al., 2012).(10%) of SEs as variable DREs in FL samples (Figure S1I). How-
ever, the proportion of variable SEs in FL samples is substantially
lower than that of conventional enhancers with altered activity
(45%–50%). The relative lack of variability in SEs most likely
reflects their role in maintaining B-cell identity. Indeed, genes
involved in immune responses and lymphocyte activation are en-
riched in the SE circuits (Table S3). We conclude that a majority
of variable DREs are conventional enhancers whose altered
function resets the transcriptional circuitry of B cells to drive
transformation.
Pathogenic FL Regulatory Circuits
To decipher the pathogenic regulatory circuitry of FL, one must
connect variable DREs to their target genes. Chromatin acces-
sibility at enhancers and nearby promoters often correlate,
providing a pattern-based strategy by which to assign regulatory
circuits (Thurman et al., 2012). Using this approach, we con-
nected variable DREs to genes within 500 kb that exhibit concor-
dant changes in chromatin at their transcription start sites (TSSs)
(Figure S2A). Approximately one-third of the variable DREs were
linked to a single TSS, whereas the majority had potential con-
nections to two or more target genes (Figure 2A). Moreover,
the average expression of genes with concordant TSS chromatin
is significantly elevated or attenuated in comparison to that of
genes near unchanged DREs (Figure 2B) or to that of all neigh-
boring genes (Figure S2B).
Nevertheless, chromatin-based correlations do not allow eval-
uation of the functional output of putative DRE-gene connec-
tions, i.e., expression levels. Therefore, we applied a new levelof stringency: concordant changes in the expression of genes
predicted to be targets of DREs by chromatin profiling (Fig-
ure S2A). Only 53% of putative target genes were verified by
this expression filter (Table S4), indicating a 47% false-positive
rate for predicting DRE-promoter connections solely via chro-
matin patterns. Approximately 40% of the circuits with altered
activity in FL samples are normally employed in the GC reaction;
these include CC- or CB-specific connections, as well as
those used by both subsets (Figure S2C). However, the majority
of altered FL circuits are not engaged in either subset of GC
B lymphocytes, indicating a widespread change in the B-cell
regulome.
The validity of connections identified by this strategy is high-
lighted by the cytokine receptor locus that includes IFNAR1,
IFNAR2, IL10RB, and IFNGR2 (Figure 2C). Activation of these
receptors alters B-cell responses, including viability and prolifer-
ation, which are enhanced. However, to our knowledge, overex-
pression of these genes has not been linked to FL. The
pathogenic circuits for each of the two augmented DREs at
the 30 end of this cluster include predicted regulatory
interactions with multiple TSSs of the receptor genes. Published
5C data for the B lymphoblastoid cell line GM12878 confirms
interactions between these DREs and regions proximal to
many of the TSSs (Sanyal et al., 2012). Thus, integrative analysis
of transcriptome and epigenome data reveals a core pathogenic
FL circuitry that incorporates regulome components from both
GC subsets. The newly defined circuitry also identifies variable
DRE connections to genes whose roles in FL pathogenesis
were previously unknown.Immunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc. 189
Figure 3. Epigenome-Centric Analyses Reveal Distinct FL Subtypes
(A) Heatmap for variable DREs with significant differences in regions of open chromatin (as measured by normalized read counts with FAIRE-seq); these dif-
ferences separate FL into two subtypes.
(B) Heatmap for genes that are differentially expressed in distinct stages of B-cell activation or differentiation (Longo et al., 2009), as determined by gene-set
enrichment analysis of microarray data (false discovery rate: q < 0.0001).Epigenome-Centric Analysis Segregates FL into Two
Distinct Subtypes
Despite significant heterogeneity in clinical behavior and
therapeutic responses, low-grade FL is uniformly classified for
prognosis and treatment (Izutsu, 2014). One source of FL hetero-
geneity could be utilization of distinct B-cell regulatory circuits
during oncogenesis. To test this, we performed unbiased hierar-
chical clustering of chromatin features for FL and normal B-cell
populations, including CCs, CBs, resting PBBs, and in-vitro-acti-
vated PBBs, which resemble plasmablasts (Tarte et al., 2002).
Unexpectedly, this epigenomic analysis revealed two distinct
FL DRE subtypes that differ significantly (p < 0.01). Whereas
the subtype 1 enhancer profile parallels that of CC, the subtype
2 profile includes DREs with activities similar to those of in-vitro-
activated PBBs (Figure 3A). Thus, enhancer profiling identifies
two distinct subtypes of FL that resemble different stages of
B-cell activation and differentiation, much like previous expres-
sion-profiling studies have segregated subtypes of DLBCL
(Alizadeh et al., 2000).
To gain insight into the genes regulated by subtype 1 and 2
DREs, we focused on a cohort shown previously to distinguish
GC B-cell populations from other mature B-cell populations
(Longo et al., 2009). Strikingly, subtype-specific DREs form reg-
ulatory circuits with >95% of these genes. Figure 3B shows
expression data for genes linked to subtype-specific DREs, con-
firming that components of CC and plasmablast transcriptional
programs are differentially engaged by enhancers specific to
subtypes 1 and 2, respectively. Importantly, when we focused
on these genes defined by our epigenome-centric approach,
the divergent expression patterns were also evident in microar-
ray data from larger FL sample sets (Figure S3A) (Compagno
et al., 2009; Dave et al., 2004). For example, a subtype 2-specific
circuit connects a variable DRE with enhanced expression of190 Immunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc.CCR7.CCR7 encodes the CCL19 and CCL21 chemokine recep-
tor (Figure S3B), which is involved in NHL retention within the
lymph node and thus provides transformed cells with a survival
advantage (Rehm et al., 2011). The two FL subtypes also have
remarkably different expression patterns for genes involved in
a range of relevant biological processes, including DNA repair
and NF-kB signaling pathways (Figure S3C).
Although sample numbers are limited, we observed no associ-
ation of either subtype with patient age, gender, tumor purity,
grade, or presence of BCL2 translocations (Tables S1 and S5).
However, patients in subtype 2weremore likely to have received
chemotherapy for lymphoma than were patients in subtype 1
(3/6 versus 2/10, respectively). Our epigenome-centric approach
uncovered two subtypes of low-grade FL characterized by
distinct enhancer profiles and linked transcriptional circuitries,
suggesting divergent modes of pathogenesis.
FL Discards Non-Essential Components of GC Circuitry
Humoral immune responses in the GC are evolutionary pro-
cesses that incorporate molecular and cellular mechanisms
unique to B lymphocytes; such mechanisms include Ig isotype
switching, somatic mutation, and B-cell receptor signaling (Vic-
tora andNussenzweig, 2012). Many of these antigen-induced re-
sponses may be dispensable or deleterious for FL cell survival.
Indeed, more than half of the DREs identified in CCs are attenu-
ated in at least one FL sample (Figure 1E). When genes con-
nected to attenuated DREs were subjected to ontology analysis,
we found enriched pathways that are most likely detrimental to
lymphomagenesis; such pathways include cell-cycle check-
points and apoptosis (Figure 4A). Many pathways critical for
the GC reaction, but presumably dispensable for generating
FL, including somatic hypermutation of Ig genes and B-cell-
mediated immunity, also were downregulated.
Figure 4. FL Suppresses REs Associated with GC Identity
(A) Heatmap representation of enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways identified from down-
regulated genes within 500 kb of attenuated DREs.
(B) Expression profiles (microarray) for TFs predicted to bind motifs in attenuated DREs. Refer to Table S6 for expression values.
(C) SPIB transcripts, as measured by qPCR, in GM12878 cells transfected with either control or SPIB shRNA. Results represent the mean ± SEM of three in-
dependent experiments.
(D) H3K27ac ChIP assays in GM12878 cells transfected with control or SPIB-specific shRNA. Associated DNA was analyzed via qPCR with primers spanning
DREs harboring SPIB-binding sites. Results represent the mean ± SEM of three independent experiments.
(E) Transcript levels for DRE target genes, as measured by qPCR, in GM12878 cells transfected with either control or SPIB-specific shRNA. Results represent the
mean ± SEM of three independent experiments. Statistical significance (unpaired t test): *p% 0.05.One strategy for decommissioning large blocks of DREs could
involve suppression of their cognate TFs. To test this possibility,
we identified TF binding motifs enriched in attenuated DREs and
found that most, including POU2F2, SPIB, and TCF3, serve key
functions in lymphocyte development and the GC reaction (Fig-
ure 4B) (Hagman and Lukin, 2006). Indeed, mRNA expression of
these TFs is considerably decreased in all FL samples compared
with CC samples, and there is relatively greater suppression of
TCF3 in subtype 1 than in subtype 2 (Figure 4B). To test whether
diminished amounts of one such TF contribute to the decommis-
sioning of DREs, we expressed a validated shRNA specific for
SPIB in GM12878 B cells (Figure 4C). We selected for focused
analysis four DREs that are known to bind the related ETS family
factor PU.1 in these cells (Neph et al., 2012), which are attenu-
ated in FL expressing low amounts of SPIB. Amounts of
H3K27ac were reduced significantly at three of the four DREs
in cells that express the SPIB-specific but not the control shRNA(Figure 4D). The loss of H3K27ac at these three DREs coincided
with attenuated expression of at least one putative target gene,
whereas the putative target for the fourth DRE was unaffected
(Figure 4E). Our findings indicate that coordinated suppression
of B cell TFs and their target REs is a key component of the path-
ologic circuitry for FL transformation and survival.
FL Usurps Regulatory Circuits from Other Cell Lineages
In addition to discarding non-essential GC circuitry, FL might
evolve by co-opting circuits from other cell lineages that promote
growth and survival. Indeed,20% (11,318) of the variable DREs
identified in FL are completely absent in all tested control B cell
populations, including CCs, CBs, TsBs, resting or activated
PBBs, and the B cell line GM12878. Nearly one-third of these
‘‘de novo’’ DREs overlap a region of open chromatin found in
at least one of 27 primary cell types (Figure S4A) (Bernstein
et al., 2012; Thurman et al., 2012). Many of the remaining deImmunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc. 191
Figure 5. Novel DREs in Pathogenic FL Regulatory Circuits
(A) Distribution of 706 de novo DREs (orange) that overlap REs in other cancer types (purple).
(B) Heatmap representation of enriched GO terms and KEGG pathways identified from upregulated genes within 500 kb of de novo DREs.
(C) RNA expression profiles (microarray) for TFs predicted to bind de novo DREs that are consistently upregulated in FL samples. Refer to Table S6 for expression
values.
(D) RNA expression profiles (microarray data) for TFs predicted to bind de novo DREs that are differentially upregulated in either subtype 1 or subtype 2 FL
samples. Refer to Table S6 for expression values.
(E) The relative expression of TFs, ranked by number of corresponding TF motifs within private DREs, in individual FL samples is compared to the average
expression in all FL samples. Additional data are shown in Figure S4C.novo DREs are shared with one or more non-B-cell cancers
(Figure 5A). The pathologic relevance of these elements is high-
lighted by a de novo DRE overlapping the promoter of an anti-
sense non-coding RNA in the HOXA10 locus. This de novo
DRE coincides with enhanced expression of HOXA10 in FL sam-
ples compared to CC samples (Figure S4B). HOXA genes are
master TFs of embryonic development and are aberrantly ex-
pressed in many cancers (Shah and Sukumar, 2010). Indeed,192 Immunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc.overexpression of HOXA10 in bone marrow is associated with
a block in B cell differentiation and induction of leukemia in
mice (Argiropoulos and Humphries, 2007). Thus, FL comman-
deers DREs that are irrelevant for normal B-cell identity or activa-
tion, suggesting that they control the expression of genes
involved in cellular transformation.
To investigate this possibility, we performed ontology analysis
on genes connected to de novo REs in our FL circuitry.
Consistent with cell-type distribution of the de novo DREs,
many of the enriched pathways govern biological or oncogenic
processes, such as vasculature development and gliomagene-
sis, in other lineages (Figure 5B). Other pathways correspond to
more general oncogenesis mechanisms, including regulation of
cell signaling and growth. Similar to attenuated DREs, the de
novo DREs are enriched in motifs for TFs that exhibit higher
expression levels across FL samples (Figure 5C). Dysregulated
TFs include those involved in general cellular transformation
(MAX, GFI1B) and the development of non-B cells (MEF2A,
RUNX2). A subset of the enriched motifs corresponds to TFs
whose augmented expression distinguishes subtype 1 from
subtype 2 FL (Figure 5D). TFs with higher expression in subtype
1 FL samples, which resemble CC samples, include BACH2, a
transcriptional repressor that cooperates with BCL6 to regulate
gene expression in GC B cells (Huang et al., 2014), as well
as TFs with diverse roles in hematopoiesis (FOXO1, GATA6).
TFs with relatively higher expression in subtype 2 FL cells,
which resemble activated B cells, include both the RELA sub-
unit of NF-kB and IRF1, a component of the MYD88 signaling
cascade (Ikushima et al., 2013). We next considered whether
variable DREs unique to individual FL samples (i.e., ‘‘private’’
DREs) arise from deregulation of additional TFs. We find that
when an FL sample expresses substantially higher levels of a
unique TF than other FL samples, its private DREs are enriched
for the binding site for that TF (Figures 5E and S4C). We
conclude that FL commandeers oncogenic regulatory circuits,
in part, by activating expression of general or lineage-inappro-
priate TFs.
Variable DREs Are Enriched for Inherited and Acquired
Sequence Alterations
Prior studies have shown that sequence variants co-localize with
regulatory regions and disrupt TF binding motifs; they thereby
provide a potential genetic source for perturbations in DRE activ-
ity and, consequently, target gene expression (Corradin et al.,
2014; Huang et al., 2014; Khurana et al., 2013; Maurano et al.,
2012). To explore whether this mechanism is active in FL, we
selected high-quality DRE sequence variants that were present
in multiple RNA-, FAIRE- or ChIP-Seq datasets in an individual
FL sample. We assigned each variant either as a SNP on the ba-
sis of its annotation in the 1000Genomes or dbSNP-All SNPs da-
tabases or as a putative somatic single-nucleotide variant (SNV).
To validate this variant-calling method, we performed Sanger
sequencing by using FL samples and patient-matched periph-
eral blood mononuclear cells (PBMCs) when available. Of 28
identified variants, 24 were confirmed (86%). Twelve were pre-
sent in FL samples and matched PBMCs, suggesting that they
are private SNPs; nine were present in the FL sample (no
matched PBMCs), and three were confirmed to be of somatic
origin (in FL samples but not PBMCs; Table S7). Thus, our infor-
matics approach for identification of DRE sequence variants is
highly accurate.
Consistent with a potential function for SNPs and SNVs in
altering DRE activity, we found that both are significantly en-
riched (p < 0.0001) in variable DREs (Figure 6A). Analysis of
disease- and trait-associated index SNPs from the GWAS cat-
alog revealed that B-cell cancer SNPs in variable DREs were
significantly enriched relative to the fraction of total SNPs inthese regions (Figure 6B). In contrast, variable DREs are
depleted for SNPs associated with other cancers and several
unrelated traits. Although somatic mutation levels vary in sub-
types of some cancers (Kandoth et al., 2013; Pasqualucci
et al., 2014), there were no significant differences in SNV load
for the variable DREs present in FL subtype 1 versus subtype
2 samples (Figure 6C). Similarly, we did not identify DRE
sequence variants significantly associated with either subtype.
Together, these findings suggest that the activity of some
DREs is altered in FL via sequence variation and that a subset
of these pathologic elements might arise from somatic mutation
during lymphomagenesis.
To explore the impact of sequence variants on DRE function,
we identified SNPs or mutations predicted to disrupt TF motifs
by using TRANSFAC and FunSEQ (Khurana et al., 2013; Matys
et al., 2006). A significantly greater fraction of motif-disrupting
variants occurred in variable than in unchanged DREs, sug-
gesting a functional role for sequence variation in altering
enhancer activity (Figure 6D). Moreover, some of these variants
overlap binding motifs for TFs important in GC B-cell biology
(Figure 6E). These TFs include POU2F2, IKZF1, and TCF3.
We selected three sequence variants, all located in attenuated
DREs, for more in-depth analysis (Figure 7). Although not
previously linked to FL, a SNP associated with familial chronic
lymphocytic leukemia (rs674313) (Slager et al., 2011) is located
in a binding motif for IKZF1, a TF that regulates cell-fate deci-
sions during lymphopoiesis. The second variant most likely
corresponds to a private SNP because it is also present in
the patient’s PBMCs but is not found in available SNP data-
bases (Table S5). The private SNP overlaps a binding site for
SP1, a ubiquitous TF that governs many biological processes,
including cell-cycle regulation and apoptosis (Archer, 2011).
The third variant is a somatic mutation that was present in the
FL sample but not in the matched PBMCs (Table S5). The
mutation is located in a predicted binding site for TCF3, a TF
important for many aspects of B-cell development and activa-
tion (Hagman and Lukin, 2006).
Binding of each TF to its predicted site in the attenuated DRE
is supported by IKZF1, SP1, and TCF3 ChIP-seq data from
GM12878 B cells (Figure 7A) (Neph et al., 2012). Importantly,
expression of target genes predicted by FL pathogenic circuitry
is also reduced in FLs harboring the altered DREs (Figure 7B).
Each of the target genes has a demonstrated role in B-cell can-
cer: allelic variants of HLA-DQA1 have been associated with an
increased risk of childhood acute lymphocytic leukemia (Ur-
ayama et al., 2013); DUSP6, a MAP kinase phosphatase specific
for ERK1 and 2, is deregulated in multiple cancers (Bermudez
et al., 2010); and IRF8, a TF that regulates BCL6 and AICDA in
GC reactions, is mutated in several types of NHL (Morin et al.,
2011; Pasqualucci et al., 2014; Wang and Morse, 2009). A func-
tional impact for the variants is demonstrated by oligonucleotide
precipitation assays. Each TF binds robustly to a sequence
corresponding to the reference allele. In contrast, binding is
substantially diminished when oligonucleotides contain the
identified variants (Figure 7C). Finally, enhancer activity of each
DRE, as measured by luciferase reporter assays, is significantly
attenuated when the reference enhancer is mutated to its corre-
sponding sequence variant (Figure 7D). To our knowledge, this is
the first reported example of an acquired mutation that occurs inImmunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc. 193
Figure 6. Variable DREs Are Enriched for Inherited and Acquired Sequence Variants
(A) Percentage of variable and unchanged DREs with either SNPs or SNVs.
(B) Enrichment or depletion of disease- or trait-associated SNPs in variable DREs.
(C) Number of SNVs within variable DREs in each FL sample.
(D) Fraction of sequence variants that disrupt TF motifs in unchanged versus variable DREs. Statistical significance for panels (A), (B), and (D) (c2 test):
****p% 0.0001.
(E) Representative disease-associated SNPs and SNVs predicted to disrupt TF motifs.an enhancer and attenuates TF binding and target-gene expres-
sion in cancer. Together, our data indicate that DRE sequence
variants, whether inherited or acquired, contribute to altered
gene-expression programs that drive lymphomagenesis.
DISCUSSION
A key question regarding lymphomagenensis is how the normal
gene-expression programs of GCB cells are dramatically altered
during transformation. We now provide a comprehensive wiring
scheme for pathogenic gene-expression circuits in a common B
cell cancer; this wiring scheme is a composite of changes to
normal GC B-cell circuitry and regulatory circuits comman-
deered from other cell lineages. Importantly, the collection of
regulatory elements incorporated into FL pathogenic circuits is
significantly enriched for sequence variants, either SNPs or so-
maticmutations, some of which disrupt TF binding and attenuate
the expression of their target genes.
Our epigenome-centric approach revealed two distinct sub-
types of low-grade FL, which is considered a single diagnostic
entity despite clinical heterogeneity. Each subtype exhibits a
characteristic pathogenic enhancer profile. The variable DREs194 Immunity 42, 186–198, January 20, 2015 ª2015 Elsevier Inc.and linked genes specific to subtype 1 most resemble the
regulatory circuits seen in CCs, whereas subtype 2 FL cells ac-
quire components of normal plasmablast circuitry. Notably, the
expression of genes linked to subtype-specific DREs largely re-
capitulates patterns observed for subtypes of DLBCL, termed
GC- and activated B cell (ABC)-DLBCL. Similar to findings in
DLBCL, in FL the distinct variable DREs and target genes most
likely reflect divergent modes of pathogenesis, whereby subtype
1 maintains survival pathways downstream of tonic B cell
receptor (BCR) signaling, as occurs in GC-DLBCL. In contrast,
subtype 2 variable DREs govern genes that are responsive to
chronic BCR signaling (as occurs in ABC-DLBCL) (Rui et al.,
2011). Our definition of FL regulatory circuits should inform
mechanistic studies into common and distinct modes of lym-
phoma pathogenesis. Researchers could use variable DREs
that distinguish subtype-specific circuits to develop new preci-
sion-medicine strategies by directly targeting these elements
with sequence-specific chromatin modifiers to reverse their
pathogenic function.
A key insight from our integrative analysis of FL regulatory cir-
cuits is the central role for TFs in driving pathogenic changes to
DRE function. Specifically, we identified distinct TF cohorts
Figure 7. Polymorphisms and Mutations
in FL-Altered DREs Disrupt Enhancer
Function
(A) UCSC Genome Browser views of H3K27ac
ChIP-seq data illustrating attenuated DREs
harboring the indicated sequence variants in FL
samples and the reference sequence in CC sam-
ples (upper 2 tracks). The bottom track shows
ChIP-seq data for the indicated TFs performed in
the GM12878 B cell line (Neph et al., 2012). Arrows
indicate the variant sequence and location in
position-weight matrices for each TF.
(B) Expression of the DRE target genes quantified
by microarray analysis.
(C) Oligonucleotide precipitation assays demon-
strate reduced TF binding in variant-containing
compared to reference sequences. Immunoblots
were probed with antibodies specific to the TF
of interest (representative of three experimental
replicates).
(D) Luciferase reporter assays performed in
lymphoma cell lines demonstrate significantly
reduced activity for the variant-containing com-
pared to reference sequences in the attenuated
DREs. Luciferase activity is presented as an n-fold
change for the enhancer vector relative to a re-
porter containing only the SV40 promoter (lucif-
erase activity for the promoter-only reporter is set
to a value of 1.0). Results represent the mean ±
SEM of three independent experiments. Statistical
significance (paired t test) was set at *p% 0.05.associated with attenuated versus enhanced activity of DREs in
FL samples. Compared with normal CC counterparts, FL cells
decommission some circuitry by attenuating the expression of
TFs that regulate GC processes that are either dispensable for
lymphomagenesis, such as Ig class-switch recombination, or
prohibitive for transformation, such as pro-apoptotic pathways.
Our study provides experimental support for this general mech-
anism and demonstrates that depletion of one such factor, SPIB,
reduces the activity of predicted enhancer targets and genes
linked in the pathogenic FL circuitry. In contrast, a second set
of TFs overexpressed in FL activate DREs that are normally silent
in all subsets ofmature B cells. The circuits targeted by these TFs
include genes involved in general oncogenesis mechanisms,
such as cell signaling, survival, and proliferation.
The central role of TFs in rewiring regulatory circuits was man-
ifested at a genetic level by enrichment of DRE sequence vari-
ants that impact TF binding. The inherited sequence variants in
FL are associated with other types of B-cell cancer and autoim-
mune disorders, suggesting that disruption of these regulatory
circuits is a shared mechanism for a spectrum of lymphocyte-Immunity 42, 186–198mediated diseases. In addition to SNPs,
we provide the first evidence, to our
knowledge, of a somatic DRE mutation
that attenuates TF binding, enhancer
function, and expression of its target
gene in cancer. The precise source of
somatic mutations remains to be estab-
lished. However, an intriguing possibility
is that some acquired SNVs arise duringB-cell activation, perhaps as off-target consequences of so-
matic hypermutation (Khodabakhshi et al., 2012).
In summary, our epigenome studies provide a rich resource
for deciphering aberrations in the transcriptional circuitry that
fosters pathogenesis of B-cell lymphoma. In particular, we find
that FL co-opts beneficial regulatory circuits and prunes poten-
tially deleterious connections to construct pathogenic cistromes
via diverse mechanisms, including inappropriate TF expression
and the acquisition of somatic mutations in DREs.
EXPERIMENTAL PROCEDURES
Detailed methods for sample collection, ChIP-seq, FAIRE-seq, and infor-
matics analyses can be found in the Supplemental Experimental Procedures.
B-Cell Isolation
Single-cell suspensions of CD19+ B lymphocytes from each FL biopsy were
isolated by physical disruption and magnetic-assisted cell sorting (MACS, Hu-
man CD19 Microbeads, Miltenyi). PBBs were isolated from blood samples by
negative sorting (Human B cell Isolation Kit II, Miltenyi) and immediately pro-
cessed (for obtaining resting PBBs) or subjected to in vitro activation with, January 20, 2015 ª2015 Elsevier Inc. 195
IL4, anti-CD40, IgM, and IgD (for obtaining activated PBBs). Tonsillar tissues
were mechanically disrupted and digested with collagenase for 1 hr. GC B
cells were isolated by MACS (CD19+ sorting) and flow cytometry so that
CD10+CD44loCXCR4+ (CB) and CD10+CD44loCXCR4- (CC) populations could
be sorted from tonsil populations (Caron et al., 2009).
ChIP- and FAIRE-seq
ChIP and FAIRE assays were performed as described (Giresi and Lieb, 2009;
Koues et al., 2008). At least 3 ng of FAIRE, ChIP, or input DNA was used for
indexed-library preparation. Samples were pooled (nine samples) and sub-
jected to 42 bp single-end sequencing.
Knockdown Experiments
Knockdown of SPIB was achieved by electroporation of control (target
sequence: 50-AAGCTGGAGTACAACTACA-30 ) or SPIB shRNA (target
sequence: 50-TACAGCTGAAGTGTGGCCCGTC-30) plasmid containing a
selectable marker (CD4). Transfected cells were purified 48 hr post transfec-
tion using magnetic bead isolation for CD4 (Stem Cell Technologies, Vancou-
ver, Canada).
Gene-Expression Analysis
RNA was purified (QIAGEN RNeasy), amplified (Nugen Ovation Pico
SL or Ovation Pico), labeled (Nugen Encore Biotin), and hybridized on Af-
fymetrix Human Gene 1.0ST arrays. Expression was quantified with
Expression Console software (v1.2.0.20) with probe-level RMA and default
settings. rRNA-depleted (Ribo-Zero, Epicenter) libraries were prepared
with TruSeq RNA sample kits with indexed adaptors (Illumina), pooled
(three libraries), and subjected to 100 bp paired-end sequencing. RNA-
seq data were aligned to the reference genome (build GRCh37/hg19)
with TopHat (Trapnell et al., 2012). Fragments per kilobase of transcript
per million fragments mapped (FPKM values) were obtained via Cufflinks
with default parameters.
Mutation Analysis
SNVs were identified from RNA- and ChIP-seq files via SAMtools (Li et al.,
2009). Variants were filtered so that non-coding SNVs common to multiple
sequencing formats could be identified, and known SNPs were removed on
the basis of comparison to all SNPs in dbSNP, build 138. SNVs predicted to
disrupt TF bindingmotifs were identified with TRANSFAC or FunSEQ (Khurana
et al., 2013; Matys et al., 2006). For 28 randomly selected SNVs, the regions
flanking the SNV positions were amplified from tumor and PBMC genomic
DNA by PCR, and the products were sequenced.
Luciferase Assays
DREs were amplified by PCR and inserted downstream of the luciferase cod-
ing sequence in the SV40 promoter-driven pGL3 plasmid (Promega, France).
Reporter vectors were transfected by electroporation into three lymphoma
cell lines: OCI-LY7 (DREs 1–10), Raji (DREs 15–16), and RL (DRE 17). Dual
luciferase assayswere performed in duplicate according to themanufacturer’s
protocol (Promega).
Oligonucleotide Precipitation Analysis
Assays were performed as described (Basu et al., 2009). 293T cells (American
Type Culture Collection) transfected with TCF3, IKZF1, or SP1 expression
plasmids were lysed in HKMG buffer (10 mM HEPES [pH 7.9], 100 mM KCl,
5 mM MgCl2, 10% glycerol, 1 mM DTT, and 1% Nonidet P-40). Lysates
were incubated overnight at 4Cwith biotinylated double-stranded oligonucle-
otides spanning the reference or variant TF sequence in the presence of a
10-fold excess of poly(dI–dC). DNA-bound proteins were collected with Neu-
trAvidin UltraLink Resin (Thermo Scientific, Waltham, MA) and assayed by
immunoblot.
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